Human abuse potential of immediate-release/extended-release versus immediate-release hydrocodone bitartrate/acetaminophen: a randomized controlled trial in recreational users of prescription opioids

References

• Blondell RD, Azadfard M, Wisniewski AM. Pharmacologic therapy for acute pain. Am Fam Physician 2013;87:766–72.
   PubMedGoogle Scholar
• McCarberg BH. Pain management in primary care: strategies to mitigate opioid misuse, abuse, and diversion. Postgrad Med 2011;123:119–30.
   PubMed Web of Science ®Google Scholar
• Cantrill SV, Brown MD, Carlisle RJ, et al. Clinical policy: critical issues in the prescribing of opioids for adult patients in the emergency department. Ann Emerg Med 2012;60:499–525.
   PubMed Web of Science ®Google Scholar
• Argoff CE, Kahan MM, Sellers EM. Preventing and managing aberrant drug-related behavior in primary care: systematic review of outcomes evidence. J Opioid Manag 2013;10:119–34.
   Google Scholar
• National Opioid Use Guideline Group. Canadian guidelines for safe and effective use of opioids for chronic non-cancer pain. McMaster University Available at http://nationalpaincentre.mcmaster.ca/opioid/. Accessed 14 October 2014.
   Google Scholar
• Romach MK, Schoedel KA, Sellers EM. Update on tamper-resistant drug formulations. Drug Alcohol Depend 2013;130:13–23.
   PubMed Web of Science ®Google Scholar
• Purdue Pharma L.P. Receives FDA approval for hysinglaTM ER (hydrocodone bitartrate) extended-release tablets CII, a once-daily opioid analgesic formulated with abuse-deterrent properties. Stamford, CT, Purdue Pharma, LP; 2014.
   Google Scholar
• EMBEDA®. Morphine sulfate and naltrexone hydrochloride. New York, NY, Pfizer, Inc; 2014.
   Google Scholar
• OxyContin® (oxycodone HCl extended-release tablets). Full Prescribing Information [package insert]. Stamford, CT, Purdue Pharma LP; 2014.
   Google Scholar
• US Food and Drug Administration. Guidance for industry abuse-deterrent opioids - evaluation and labeling. Center for Drug Evaluation and Research; Silver Spring, MD: 2013.
   Google Scholar
• Jones JD, Sullivan MA, Manubay J, Vosburg SK, Comer SD. The subjective, reinforcing, and analgesic effects of oxycodone in patients with chronic, non-malignant pain who are maintained on sublingual buprenorphine/naloxone. Neuropsychopharmacology 2011;36:411–22.
   PubMedGoogle Scholar
• Morton T, Kostenbader K, Montgomery J, Devarakonda K, Barrett T, Webster L. Comparison of subjective effects of extended-release versus immediate-release oxycodone/acetaminophen tablets: a randomized trial. Postgrad Med 2014;126:20–32.
   PubMed Web of Science ®Google Scholar
• Schoedel KA, McMorn S, Chakraborty B, Potts SL, Zerbe K, Sellers EM. Positive and negative subjective effects of extended-release oxymorphone versus controlled-release oxycodone in recreational opioid users. J Opioid Manag 2011;7:179–92.
   PubMedGoogle Scholar
• Shram MJ, Sathyan G, Khanna S, et al. Evaluation of the abuse potential of extended release hydromorphone versus immediate release hydromorphone. J Clin Psychopharmacol 2010;30:25–33.
   PubMed Web of Science ®Google Scholar
• Zacny JP, Gutierrez S. Characterizing the subjective, psychomotor, and physiological effects of oral oxycodone in non-drug-abusing volunteers. Psychopharmacology (Berl) 2003;170:242–54.
   PubMed Web of Science ®Google Scholar
• Zacny JP, Gutierrez S. Within-subject comparison of the psychopharmacological profiles of oral hydrocodone and oxycodone combination products in non-drug-abusing volunteers. Drug Alcohol Depend 2009;101:107–14.
   PubMedGoogle Scholar
• Zacny JP, Lichtor SA. Within-subject comparison of the psychopharmacological profiles of oral oxycodone and oral morphine in non-drug-abusing volunteers. Psychopharmacology (Berl) 2008;196:105–16.
   PubMed Web of Science ®Google Scholar
• Preston KL, Sullivan JT, Testa M, Jasinski DR. Psychopharmacology and abuse potential of transnasal butorphanol. Drug Alcohol Depend 1994;35:159–67.
   PubMedGoogle Scholar
• Williams EJ. Experimental designs balanced for the estimation of residual effects of treatments. Australian J Sci Res 1949;A2:149–68.
   Google Scholar
• US Food and Drug Administration. FDA recommends health care professionals discontinue prescribing and dispensing prescription combination drug products with more than 325 mg of acetaminophen to protect consumers [press release]. Available at http://www.fda.gov/safety/medwatch/safetyinformation/safetyalertsforhumanmedicalproducts/ucm381650.htm. Accessed 29 August 2014.
   Google Scholar
• Martin WR, Sloan JW, Sapira JD, Jasinski DR. Physiologic, subjective, and behavioral effects of amphetamine, methamphetamine, ephedrine, phenmetrazine, and methylphenidate in man. Clin Pharmacol Ther 1971;12:245–58.
   PubMed Web of Science ®Google Scholar
• SAS Institute, Inc. SAS OnlineDoc® 9.1. Available at: http://support.sas.com/91doc/docMainpage.jsp. Accessed 29 August 2014.
   Google Scholar
• Butler SF, Fernandez KC, Chang A, et al. Measuring attractiveness for abuse of prescription opioids. Pain Med 2010;11:67–80.
   PubMed Web of Science ®Google Scholar
• Fisher MA, Glass S. Butorphanol (Stadol): a study in problems of current drug information and control. Neurology 1997;48:1156–60.
   PubMed Web of Science ®Google Scholar
• Vosburg SK, Jones JD, Manubay JM, Ashworth JB, Benedek IH, Comer SD. Assessment of a formulation designed to be crush-resistant in prescription opioid abusers. Drug Alcohol Depend 2012;126:206–15.
   PubMed Web of Science ®Google Scholar
• Bartholomäus J, Arkenau-Maric E, Galia E. Opioid extended-release tablets with improved tamper-resistant properties. Expert Opin Drug Deliv 2012;9:879–91.
   PubMed Web of Science ®Google Scholar
• US Food and Drug Administration. FDA statement: original Opana ER relisting determination. Available at: http://www.fda.gov/Drugs/DrugSafety/ucm351357.htm. Accessed 22 July 22 2014.
   Google Scholar
• Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J Royal Stat Soc Ser B 1995;57:289–300.
   Google Scholar